LSV Asset Management Purchases New Position in Henry Schein, Inc. $HSIC

LSV Asset Management purchased a new stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,200 shares of the company’s stock, valued at approximately $1,224,000.

Several other institutional investors and hedge funds also recently made changes to their positions in HSIC. AQR Capital Management LLC increased its position in shares of Henry Schein by 47.3% during the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after acquiring an additional 9,756 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Henry Schein by 1.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after purchasing an additional 229 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Henry Schein in the first quarter worth approximately $676,000. Cetera Investment Advisers boosted its holdings in Henry Schein by 12.9% in the second quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock worth $406,000 after purchasing an additional 637 shares during the last quarter. Finally, First Trust Advisors LP boosted its holdings in Henry Schein by 0.8% in the second quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock worth $16,154,000 after purchasing an additional 1,669 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Trading Up 2.4%

Shares of Henry Schein stock opened at $75.67 on Thursday. The company’s fifty day simple moving average is $74.32 and its 200-day simple moving average is $75.77. The stock has a market capitalization of $8.62 billion, a PE ratio of 22.86, a P/E/G ratio of 1.85 and a beta of 0.82. Henry Schein, Inc. has a 1-year low of $61.94 and a 1-year high of $89.29. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.75.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.12. The business had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company’s revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities analysts anticipate that Henry Schein, Inc. will post 5.32 earnings per share for the current year.

Insider Buying and Selling at Henry Schein

In related news, EVP Mark E. Mlotek sold 5,925 shares of Henry Schein stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total transaction of $478,740.00. Following the transaction, the executive vice president owned 80,554 shares in the company, valued at approximately $6,508,763.20. The trade was a 6.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Philip A. Laskawy sold 2,844 shares of Henry Schein stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $80.36, for a total transaction of $228,543.84. Following the transaction, the director owned 21,961 shares in the company, valued at approximately $1,764,785.96. This trade represents a 11.47% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 67,565 shares of company stock worth $5,468,572. Insiders own 0.89% of the company’s stock.

Analyst Upgrades and Downgrades

HSIC has been the topic of several research reports. BTIG Research initiated coverage on shares of Henry Schein in a report on Thursday, April 16th. They issued a “neutral” rating on the stock. Weiss Ratings restated a “hold (c+)” rating on shares of Henry Schein in a report on Monday, May 4th. JPMorgan Chase & Co. raised their target price on shares of Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Mizuho dropped their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Finally, Barrington Research set a $97.00 target price on shares of Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $86.83.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.